CurrentBlue Cross Blue Shield - MassachusettsPolicy 322

Hematopoietic stem-cell transplantation for Waldenstrom macroglobulinemia

Defines medical necessity and prior-authorization requirements for autologous and allogeneic hematopoietic stem-cell transplantation (HCT) for members with Waldenstrom macroglobulinemia; applies to commercial products (Managed Care HMO/POS, PPO, Indemnity).

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicyHematopoietic stem-cell transplantation for Waldenstrom macroglobulinemia

Policy CodePolicy 322

Change TypeCoding and administrative clarifications

Effective Date

Next Review Date

Key ActionSubmit precertification/prior authorization requests using Authorization Manager and include the servicing provider's NPI and the facility NPI with clinical documentation demonstrating diagnosis, chemosensitivity, and salvage therapy intent.

SourceLink

POLICY UPDATE CHANGES

Coding information was clarified on 10/2025.

Prior authorization requests via Authorization Manager were included (9/2023).

Medicare information was removed (1/2023) and redirected to MP #132 for local/national coverage determinations.

Medically necessaryCoverage stance for autologous HCT

InvestigationalCoverage stance for allogeneic HCT

Prior auth requiredAuthorization requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Medical Necessity Criteria for HCT in Waldenstrom Macroglobulinemia

Autologous hematopoietic stem-cell transplantation (HCT) — Medical necessity

Autologous HCT may be considered medically necessary as salvage therapy when ALL of the following are met:

ALL of the following

Diagnosis of Waldenstrom macroglobulinemia
Disease is chemosensitive (responsive to prior therapy)
Use is as salvage therapy (typically consolidation when disease in remission)

Allogeneic hematopoietic stem-cell transplantation (HCT) — Investigational

Allogeneic HCT for Waldenstrom macroglobulinemia is considered investigational (not standard therapy).

ANY of the following

Allogeneic HCT for treatment of Waldenstrom macroglobulinemia (recommended only in context of clinical trials)

General treatment indications for initiating therapy in Waldenstrom macroglobulinemia (contextual clinical criteria)

Treatment (and thus consideration of HCT approaches) is indicated only in symptomatic patients when ONE or more of the following are present:

ANY of the following

Hemoglobin concentration < 10 g/dL< 10 g/dL
Platelet count < 100,000/mL< 100,000/mL
Significant adenopathy or organomegaly
Symptomatic IgM-related hyperviscosity (>= 750 g/L)>= 750 g/L

Relevant Billing Codes

Covered / Applicable CPT codes (informational - coverage depends on criteria)CPTCovered

38241

Hematopoietic progenitor cell (HPC) transplantation, autologous

Covered / Applicable HCPCS codes (informational - coverage depends on criteria)HCPCSCovered

S2150

Bone marrow or blood-derived peripheral stem-cell harvesting and transplantation, autologous or allogeneic, including pheresis, high-dose chemotherapy, and post-transplant care in the global definition

Investigational CPT codesCPTNot Covered

38240

Bone marrow or blood-derived peripheral stem-cell transplantation; allogeneic

Investigational HCPCS codesHCPCSNot Covered

S2142

Cord blood-derived stem-cell transplantation, allogeneic

Authorization and Documentation Requirements

Prior Authorization

Precertification / prior authorization required

Precertification/prior authorization is required for services described in this policy. Providers must submit initial authorization requests using Authorization Manager and include the servicing provider's NPI and the facility NPI where services will be performed.

38241
S2150
38240
S2142

Documentation Required

Clinical documentation to support medical necessity

For autologous HCT, documentation should demonstrate diagnosis of Waldenstrom macroglobulinemia, that the disease is chemosensitive (responsive to prior therapy), and that HCT is being requested as salvage therapy; include relevant laboratory values and clinical findings aligned with treatment indications such as hemoglobin, platelet count, and evidence of symptomatic IgM-related hyperviscosity.

Clinical and Evidence Context

Waldenstrom macroglobulinemia (WM) is a lymphoplasmacytic lymphoma characterized by an associated IgM monoclonal gammopathy and a characteristic pattern of bone marrow infiltration. It is an uncommon clonal B‑cell disorder (approximately 1%–2% of hematologic malignancies) with a median patient age in the mid‑60s and a variable median survival of about 5 to 10 years depending on clinical prognostic factors.

Treatment is indicated only for symptomatic patients. Clinical and laboratory triggers for initiating therapy include hemoglobin < 10 g/dL, platelet count < 100,000/mL, significant adenopathy or organomegaly, and symptomatic IgM‑related hyperviscosity (eg, ≥ 750 g/L), as well as severe neuropathy, amyloidosis, cryoglobulinemia, cold‑agglutinin disease, or evidence of disease transformation.

Autologous hematopoietic cell transplantation (autologous HCT) uses the patient’s own harvested stem cells and is generally employed as salvage or consolidation therapy for patients whose disease is chemosensitive (demonstrates measurable response to prior chemotherapy). Autologous HCT carries risks related to high‑dose chemotherapy and preengraftment infections but does not produce graft‑versus‑host disease.

Allogeneic HCT (using donor stem cells) involves additional risks from conditioning regimens and long‑term immunosuppression, including graft‑versus‑host disease and higher treatment‑related morbidity and mortality. Because of these greater risks and limited evidence, allogeneic HCT for WM is recommended primarily within the context of clinical trials rather than as standard therapy.

The evidence base for HCT in WM is limited. Published data comprise primarily case series and registry analyses with relatively small patient numbers; reported 5‑year overall survival estimates have varied (registry analyses suggested approximately 68.5% after autologous HCT and 52% after allogeneic HCT). There is a lack of controlled studies, and clinical guidelines and expert input support autologous HCT as salvage therapy for chemosensitive disease while reserving allogeneic HCT for clinical‑trial settings.

Defined Terms

Definitions

ChemosensitiveDisease that has demonstrated measurable response to prior chemotherapy regimens.

Autologous HCTHematopoietic stem-cell transplantation using the patient's own harvested stem cells.

Allogeneic HCTHematopoietic stem-cell transplantation using stem cells from a donor.

Policy Changes

2025-10clarifiedLatest

Operational coding clarifications only; policy statements unchanged.

2023-09clarified

Policy clarified to require prior authorization requests be submitted using Authorization Manager and described required data elements (servicing provider NPI and facility NPI).

2023-01revised

Medicare information removed from this policy and redirected to MP #132 for local and national coverage determination references.